You just read:

Tolerx Presents Research at European Diabetes Meeting and Enrolls First Patient in Europe in the DEFEND-2 Phase 3 Clinical Study in Type 1 Diabetes

News provided by

Tolerx, Inc.

Sep 23, 2010, 07:30 ET